archive-com.com » COM » E » EY.COM

Total: 2294

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • EY Assurance - EY - Global
    Strategic Growth Markets How we help Entrepreneurship EY SGM Initial public offering Venture capital Family business services Transactions About Transaction Advisory Services Corporate Development Divestiture Advisory Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Life Sciences assurance services Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Life Sciences assurance services You can count on us to provide different types of assurance services to help validate critical information being communicated to an entity s stakeholders Additionally our assurance professionals leverage the skills and knowledge of our entire life sciences practice to bring a clear perspective and relevant insight to management audit committees and other key stakeholders We can provide attestation services as required by global or local regulations including Financial statement attestation including compliance with SEC reporting requirements and IFRS Fraud investigation and dispute services including contract dispute and royalty reviews Internal control compliance attestation Assistance with mergers and acquisitions including buy side and sell side due diligence Financial accounting advisory services Performance of agreed upon procedures and related reporting Climate change and sustainability reporting IPO readiness assessments Government contract and grant compliance attestation Related content FASB proposed guidance Proposed amendments to new revenue guidance on licenses and performance obligations would affect life sciences entities EY Webcast Revenue recognition standard for life sciences companies Join us on 15

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-Sciences_Assurance (2016-02-10)
    Open archived version from archive


  • Tax - EY - Global
    Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Life Sciences tax services Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Life Sciences tax services We have created a network of tax advisors who understand the complex realities of the life sciences marketplace Our Life Sciences tax services cover the breadth of advisory and compliance services for both corporate and personal tax clients Business Tax We provide corporate and business connected individual tax advisory and reporting services throughout every stage of the tax life cycle planning accounting compliance and controversy Human Capital We offer tax advisory and compliance services to companies and their international or domestic assignees Our offerings cover identification and mitigation of employment related risks These services include Global mobility advisory Assignment administration Process risk assessments Business immigration Expatriate tax return processing We also advise clients on global talent management performance and reward programs Indirect Tax We focus on advisory and compliance services for all aspects and types of indirect tax including value added tax VAT goods and services tax customs duties and environmental levies Indirect taxes affect the supply chain and the financial system and pose a unique challenge to multi national tax functions since they must be managed accurately and in real time International Tax We provide corporate income tax advice on cross border

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-Sciences_Tax (2016-02-10)
    Open archived version from archive

  • Transactions - EY - Global
    Climate Change and Sustainability Services Financial Accounting Advisory Services Financial Statement Audit Fraud Investigation Dispute Services Tax About Our Global Tax Services Country Tax Advisory Cross Border Tax Advisory Global Trade Global Compliance and Reporting Human Capital Private Client Services Law Tax Accounting Tax Performance Advisory Tax Policy and Controversy Transaction Tax VAT GST and Other Sales Taxes Transfer Pricing and Operating Model Effectiveness Strategic Growth Markets How we help Entrepreneurship EY SGM Initial public offering Venture capital Family business services Transactions About Transaction Advisory Services Corporate Development Divestiture Advisory Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Life Sciences transactions advisory services Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Life Sciences transactions advisory services Executing on the investment strategy In today s market the life sciences companies that can define a clear strategy deploy capital effectively against that strategy and continue to innovate will win Having the right advisors who understand your investment strategy know your team have the relevant transaction skills and industry knowledge and are ready when you are can help make the difference How we can help The Life Sciences Capital Agenda framework helps connect your overall capital strategy to our services as you focus on the cornerstones of preserving optimizing investing and raising capital It also helps you consider capital options

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-Sciences_Transactions (2016-02-10)
    Open archived version from archive

  • Life Sciences Contacts - EY - Global
    Retail Financial Services Wealth Asset Management Banking Capital Markets Insurance Government Public Sector Health Life Sciences Media Entertainment Mining Metals Oil Gas Power Utilities Private Equity Real Estate Hospitality Construction Technology Telecommunications Services Advisory Actuarial Customer Cybersecurity Finance Financial Services Risk Management Internal Audit People Advisory Services Program Management Risk Assurance Risk Transformation Strategy Supply Chain and Operations Technology Assurance About Assurance Services Accounting Compliance and Reporting Climate Change and Sustainability Services Financial Accounting Advisory Services Financial Statement Audit Fraud Investigation Dispute Services Tax About Our Global Tax Services Country Tax Advisory Cross Border Tax Advisory Global Trade Global Compliance and Reporting Human Capital Private Client Services Law Tax Accounting Tax Performance Advisory Tax Policy and Controversy Transaction Tax VAT GST and Other Sales Taxes Transfer Pricing and Operating Model Effectiveness Strategic Growth Markets How we help Entrepreneurship EY SGM Initial public offering Venture capital Family business services Transactions About Transaction Advisory Services Corporate Development Divestiture Advisory Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Contact leaders from the EY Global Life Science Center Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Contact leaders from the EY Global Life Science Center Global Life Sciences Leader Glen Giovannetti 1 617 374 6218 Global Pharmaceutical Leader and Global Life Sciences Markets Leader Patrick Flochel 41 58 286 41 48

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-Sciences_Contact-us (2016-02-10)
    Open archived version from archive

  • Life Sciences Press - EY - Global
    Other Sales Taxes Transfer Pricing and Operating Model Effectiveness Strategic Growth Markets How we help Entrepreneurship EY SGM Initial public offering Venture capital Family business services Transactions About Transaction Advisory Services Corporate Development Divestiture Advisory Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Press Release Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Press Release San Diego 6 October 2015 The global medtech industry struggles to sustain growth putting future innovation at risk Jakarta 29 June 2015 EY shines spotlight on Indonesia s growing health care sector through its ripe investment opportunities Philadelphia 15 June 2015 Biopharma Global biotech industry continues to sizzle as market capitalization surpasses US 1 trillion San Francisco 12 January 2015 Biopharma M A surges to over US 200b in 2014 as companies seek focus scale and growth Cleveland Ohio US 29 October 2014 EY joins HealthXL global health care collaboration Chicago 7 October 2014 Global medtech industry needs to better differentiate products or face commoditization Boston and San Diego 24 June 2014 Global biotechnology industry needs new paradigm for drug R D Zurich 12 May 2014 Sinking profits and accelerated consolidation Big Pharma facing historic upheavals Boston 7 May 2014 Global pharmaceutical industry has significant opportunities for deeper engagement with payers but contingent upon restoring trust San Francisco 13 January 2014 Big

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-Sciences_Press-releases (2016-02-10)
    Open archived version from archive

  • EY - Life sciences events, conferences, forums, roundtables, and webcasts - EY - Global
    Mining Metals Oil Gas Power Utilities Private Equity Real Estate Hospitality Construction Technology Telecommunications Services Advisory Actuarial Customer Cybersecurity Finance Financial Services Risk Management Internal Audit People Advisory Services Program Management Risk Assurance Risk Transformation Strategy Supply Chain and Operations Technology Assurance About Assurance Services Accounting Compliance and Reporting Climate Change and Sustainability Services Financial Accounting Advisory Services Financial Statement Audit Fraud Investigation Dispute Services Tax About Our Global Tax Services Country Tax Advisory Cross Border Tax Advisory Global Trade Global Compliance and Reporting Human Capital Private Client Services Law Tax Accounting Tax Performance Advisory Tax Policy and Controversy Transaction Tax VAT GST and Other Sales Taxes Transfer Pricing and Operating Model Effectiveness Strategic Growth Markets How we help Entrepreneurship EY SGM Initial public offering Venture capital Family business services Transactions About Transaction Advisory Services Corporate Development Divestiture Advisory Services Lead Advisory Operational Transaction Services Restructuring Strategy Services Transaction Support Transaction Tax Valuation Business Modelling Specialty Services Climate Change and Sustainability Services CertifyPoint China Overseas Investment Network Family Business Services French Business Network Global Business Network Japan Business Services Careers Students The EY difference Your role here Your development Life at EY Joining EY Global Delivery Network Experienced Advisory Assurance Tax Transactions Industries The EY difference Your development Life at EY Joining EY Global Delivery Network Alumni Home Industries Life Sciences Life Sciences events Life Sciences Overview About our Life Sciences services Advisory Assurance Tax Transactions Library Contacts Press Events Share Life Sciences events Connect with key industry leaders extend your personal network and gain actionable insights and knowledge join us at these upcoming events sponsored our Global Life Sciences Center Digital Pharma Advances conference 27 January 2016 London UK Sustaining innovation driving growth in the age of healthcare disruption 25 February 2016 Boston MA Assurance CBI Accounting and Reporting

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Life-sciences---events (2016-02-10)
    Open archived version from archive

  • EY - Beyond borders: unlocking value - EY - Global
    by a 20 increase in spending in the US This is the first time since the onset of the global financial crisis that R D growth has outpaced revenue growth Net income slips Net income declined by US 0 8b driven in part by the US 3 7b increase in R D expenditures during the year Market capitalization skyrockets Market capitalization grew 65 to US 791 8b catalyzed by strong performances from commercial leaders which increased enthusiasm in the sector overall Funding soars Biotech companies in North America and Europe raised US 31 6b in 2013 a sharp increase from the US 28 7b raised in 2012 and the second highest total since 2003 Fifty biotechs in the US Canada and Europe debuted on the public markets in 2013 raising US 3 5b a 300 increase compared to 2012 and the highest one year total since 2000 Innovation capital defined as the amount of equity capital raised by companies with less than US 500m in revenues increased by 36 and comprised the majority of total funding for the first time since 2010 VC holds steady Venture capital raised by companies in North America and Europe totaled US 5 8b up slightly from the US 5 5b raised the prior year M A Where s pharma The total value of mergers and acquisitions involving US or European biotechs equaled US 55 7b an increase of 106 from 2012 But that upswing was driven by three mega mergers with two of the year s largest acquisitions coming surprisingly from a medtech and a specialty pharma OTC company Meantime acquisitions by increasingly active biotech buyers US 21b dwarfed those by big pharma companies as the value of pharma biotech acquisitions grew by only 2 from 2012 to 2013 Excluding the Amgen Onyx Pharmaceuticals mega merger biotech biotech deal making increased in value 68 during the same period to US 10 6b The challenge of unlocking value Despite the strong overall financial results most biotech companies operate in a resource constrained environment increasing the need to conduct R D in capital efficient ways In fact R D remains a central if not the central point of value leakage for biopharmaceutical companies Critically the failure rate for drugs in Phase III is too high around 40 according to a team of researchers at Sagient Research Systems and Biotechnology Industry Organization BIO Since the cost of R D increases sharply from one phase of clinical development to the next failing in Phase III is a very inefficient use of capital that could have been better deployed on other assets Meanwhile other trends e g market entry agreements in which payers reimburse companies based on the performance of their products or strategic alliances with milestones tied to commercial performance rather than clinical trial results make it imperative for companies to better measure and capture the value that their products create To unlock value from R D we recommend three strategies Adaptive clinical trials The long standing clinical

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/EY-beyond-borders-unlocking-value (2016-02-10)
    Open archived version from archive

  • Beyond borders Matters of evidence biotechnology industry report 2013 - Point of view matters of evidence - EY - Global
    interesting divide between how companies are approaching matters of efficiency and matters of evidence Our findings indicate an implementation gap at most small to mid size companies when it comes to gathering evidence to demonstrate the value of products under development This implementation gap has implications for the ability of these companies to raise capital obtain attractive deal valuations and be successfully reimbursed for their drugs upon approval While most respondents consider all of the strategic imperatives important or very important they are much more focused on implementing matters of efficiency than matters of evidence Points of resistance in biotech Why is this happening Despite near universal recognition of the importance of demonstrating value many biotech companies do not think these trends will appreciably affect their businesses in the near future There are several points of resistance Confront the points of resistance Myth 1 This is only relevant for commercial stage companies Strategic and financial investors want evidence that will be compelling to payers Are you entering negotiations with the data they want or the data you have Myth 2 We can t afford this Investing in evidence doesn t have to be expensive and could well be a prudent use of resources Yes you can afford to do this More important can you afford not to Myth 3 Strong science will always get paid for Payers aren t paying for science they are paying for value Can you demonstrate how your breakthrough adds economic value to the system Myth 4 This won t affect my disease segment Nobody is immune from these trends Do you understand how they will affect your business Myth 5 These trends won t become real in the near term Change is coming faster than many might have expected Are you moving forward or assuming that time is on your side Guiding principles for demonstrating value To succeed companies will need to revisit their approaches to R D It will be imperative to monitor evolving standards of care A model we call the value pathway can help identify the biggest unmet needs or failures that payers will be most focused on Companies will then need to align their offerings to fill these value leakages and design clinical trials to develop evidence that is compelling for payers Companies of all sizes and focus areas can take steps today to invest in the type of evidence that will be compelling to investors and payers Such steps could include engaging stakeholders earlier on issues of value and reimbursement rethinking trial design and exploring pre competitive data alliances To succeed in the evidence driven systems that are fast approaching biotech companies regardless of their size segment or stage of development will need to recalibrate R D and commercialization based on five guiding principles Embrace the new guiding principles Principle 1 Define your value proposition Even in early development seek to understand your product s contribution and why payers would value it Solicit input from key stakeholders Refine your value

    Original URL path: http://www.ey.com/GL/en/Industries/Life-Sciences/Beyond-borders-Matters-of-evidence-biotechnology-industry-report-2013---Point-of-view-matters-of-evidence (2016-02-10)
    Open archived version from archive



  •